Last reviewed · How we verify
Dexycu, 9% Intraocular Suspension — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Dexycu, 9% Intraocular Suspension (Dexycu, 9% Intraocular Suspension) — Silverstein Eye Centers.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dexycu, 9% Intraocular Suspension TARGET | Dexycu, 9% Intraocular Suspension | Silverstein Eye Centers | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dexycu, 9% Intraocular Suspension CI watch — RSS
- Dexycu, 9% Intraocular Suspension CI watch — Atom
- Dexycu, 9% Intraocular Suspension CI watch — JSON
- Dexycu, 9% Intraocular Suspension alone — RSS
Cite this brief
Drug Landscape (2026). Dexycu, 9% Intraocular Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/dexycu-9-intraocular-suspension. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab